Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Daniel Nazzaro

Nurse Practitioner Boston, MA Nurse Practitioner

NPI 1770166944 CMS profile 10607310

1 Boston Medical Ctr Pl, Boston, MA 02118

Open in the dashboard

General payments

$2,907

115 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Daniel Nazzaro of Boston, MA is reported in the CMS Open Payments database as having received $2,907 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $244 9
2023 General $1,491 52
2022 General $802 41
2021 General $370 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Nazzaro
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Daniel Nazzaro were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Daniel Nazzaro Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $370 $135 $40–$426 $132
2022 $802 $152 $48–$470 $149
2023 $1,491 $166 $54–$529 $160
2024 $244 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Astellas Pharma US Inc $473 17 payments
  2. Dentsply Ih AB $415 14 payments
  3. ConvaTec Inc. $207 6 payments
  4. Janssen Biotech, Inc. $197 10 payments
  5. Endo Pharmaceuticals Inc. $171 7 payments
  6. Myriad Genetic Laboratories, Inc. $150 3 payments
  7. Urovant Sciences Inc $139 9 payments
  8. Progenics Pharmaceuticals, Inc. $130 2 payments
  9. Antares Pharma, Inc. $125 6 payments
  10. 180 Medical, Inc. $100 4 payments
  11. Other $800 37 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $2,637 112 payments
  2. Education $270 3 payments
Products named General payments · program years 2021–2024
  1. LoFric $438 15 payments
  2. GENTLECATH $225 7 payments
  3. ERLEADA $197 10 payments
  4. GEMTESA $177 11 payments
  5. AVEED $171 7 payments
  6. XIAFLEX $171 7 payments
  7. XYOSTED $132 6 payments
  8. PYLARIFY $130 2 payments
  9. MYRBETRIQ $124 9 payments
  10. BRACAnalysis CDx $120 1 payment
  11. Other $1,189 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

97

Median for Nurse Practitioner: 389

Drug cost

$1,601

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tamsulosin Hcl Generic 64 $990
Finasteride Generic 33 $611

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record